News | Heart Valve Technology | May 03, 2017

Baylor Jack and Jane Hamilton Heart and Vascular Hospital Implants CoreValve Evolut Pro Valve

Team is first in United States for specific valve-in-valve case

Baylor Jack and Jane Hamilton Heart and Vascular Hospital Implants CoreValve Evolut Pro Valve

May 3, 2017 — The Baylor Jack and Jane Hamilton Heart and Vascular Hospital (BHVH) transcatheter aortic valve replacement (TAVR) team recently placed the first commercially approved CoreValve Evolut Pro system in Texas. This is also the first Evolut Pro valve placed in a failed bioprosthetic (tissue) aortic valve in the United States.

“The Evolut PRO has a unique ‘skirt’ around the valve that helps minimize leakage; one of the greatest potential risks for TAVR patient outcomes,” said Robert Stoler, M.D., co-medical director of cardiology and medical director, Baylor Heart and Vascular Hospital catheterization lab. “In this procedure, we replaced an old, surgically implanted bioprosthetic aortic valve using a minimally invasive approach, without open-heart surgery.”

During a catheter-based TAVR procedure, an interventional cardiologist or cardiothoracic surgeon makes a small incision in the leg (transfemoral approach), upper chest (direct aortic approach) or shoulder (subclavian approach) to access the vasculature, and then guides the new valve into position to replace the failing aortic valve. Once in place, the device expands and takes over the original valves function to enable blood to flow efficiently out of the heart.

“The addition of the Evolut PRO valve to the program at BHVH continues to bring an advanced generation of research and commercially available valves to aortic stenosis patients in the North Texas region,” Stoler added. “We are pleased to be the first in Texas and one of the first in the U.S. to use this new technology.”

Aortic stenosis is a common problem caused by a narrowing of the heart’s aortic valve due to excessive calcium deposits on the valve leaflets. When the valve narrows, it does not open or close properly, making the heart work harder to pump blood throughout the body. Eventually, this may cause the heart to weaken, potentially leading to heart failure and increased risk for sudden cardiac death.

Interventional cardiologists and cardiothoracic surgeons on the BHVH medical staff have performed TAVR procedures in patients with aortic stenosis for more than five years and recently reached their 500th TAVR.

For more information: www.medtronic.com

Related Content

The Edwards Konect Resilia aortic valved conduit (AVC).
News | Heart Valve Technology | July 15, 2020
July 15, 2020 —  The U.S. Food and Drug Administration (FDA) granted clearance for the Edwards Lifesciences Corp.
The Foldax Tria surgical valve reimagines the heart valve by incorporating a new, proprietary biopolymer, what the vendor calls LifePolymer, with an innovative valve design intended to eliminate calcification, withstand stresses and strains without failure, and restore patient quality of life without lifelong use of anticoagulants. Tria is also the first heart valve to be robotically manufactured, reducing variability, enabling high precision, repeatability and better quality control.
News | Heart Valve Technology | June 23, 2020
June 23, 2020 – Heart valve start-up Foldax is looking to reinventi
SMT Enters Structural Heart Market With Acquisition of Vascular Concepts. The company's Hydra TAVR (TAVI) valve gained European CE mark clearance in June 2020.
News | Heart Valve Technology | June 19, 2020
June 19, 2020 — SMT (Sahajanand Medical Technologies Pvt.
SMT (Sahajanand Medical Technology Private Ltd.), a leading medical device company of India focused on cardiology, announced it Hydra transcatheter aortic valve replacement (TAVR) device received European CE mark approval. It is indicated for the treatment of patients diagnosed with aortic stenosis. #SMT #HYDRA #TAVR

The self-expanding SMT Hydra transcatheter aortic valve replacement (TAVR) device.

Feature | Heart Valve Technology | June 09, 2020
June 9, 2020 — SMT (Sahajanand Medical Technology Private Ltd.), a leading medical device company in India focused on
News | Heart Valve Technology | June 08, 2020
June 8, 2020 — Edwards Lifesciences Corp.
Edwards Lifesciences Pascal Tricuspid Valve Transcatheter Repair System Approved in Europe
News | Heart Valve Technology | May 18, 2020
May 18, 2020 — The Edwards Lifesciences Corp.
Key TAVR Takeaways From ACC 2020
Feature | Heart Valve Technology | April 20, 2020 | Dave Fornell, Editor
Some U.S.
Abbott announced its TriClip Transcatheter Tricuspid Valve Repair (TTVR) System has received European CE mark clearance as a non-surgical treatment for people with a tricuspid valve regurgitation (TR). 
Feature | Heart Valve Technology | April 09, 2020
April 9, 2020 — Abbott announced its TriClip Transcatheter Tricuspid Valve Repair (TTVR) System has received European
The Edwards Lifesciences Cardioband for tricuspid valve regurgitation. #COVID19 #coronavirus

The Edwards Lifesciences Cardioband for tricuspid valve regurgitation is one of the device trials being paused for the duration of the COVID-19 outbreak.

News | Heart Valve Technology | March 30, 2020
March 30, 2020 — Edwards Lifesciences Corp.